baricitinib vs filgotinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: JAK · full Rheumatoid Arthritis pipeline
baricitinib · Olumiant
Marketed by Eli Lilly and partners
NCT01710358 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo-controlled trial using a validated composite measure of rheumatoid arthritis response, and significantly more patients responded on baricitinib than on placebo.
Next expected readout: March 2027 · NCT04870203 (registry estimate)
Reported efficacy
Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20) (Week 12): ACR20 response at Week 12 (primary endpoint, 290 randomized, 145 per arm): 58.6% baricitinib 4mg vs 28.3% placebo (OR 4.1, 95% CI 2.5-6.9; p=0.001) (met)
Result source: NCT02265705
filgotinib · Jyseleca
Marketed by Gilead Sciences and partners
NCT02873936 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 449 patients; the primary endpoint, ACR20 response at week 12 (a validated rheumatoid-arthritis disease-activity measure), was significantly higher with both filgotinib doses than placebo (66.0% and 57.5% vs 31.1%, both p<0.001).
Next expected readout: April 2029 · NCT06687551 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001) (met)
Result source: NCT02889796
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | baricitinib | filgotinib |
|---|---|---|
| ACR20 | 61.7% vs 39.5%+22.2 vs placeboNCT0172105711 other results
| 76.6% vs 49.9%+26.7 vs placeboNCT0288979651 other results
|
| ACR50 | 44.1% vs 21.5%+22.6 vs placeboNCT0172105713 other results
| 64.2% vs 66%−1.8 vs placeboNCT0288979687 other results
|
| ACR70 | 24.2% vs 7.9%+16.3 vs placeboNCT0172105717 other results
| 44.4% vs 37.7%+6.7 vs placeboNCT0288979687 other results
|
| DAS28-CRP remission | —Trial running · NCT04870203 | 54.5% vs 50.8%+3.7 vs placeboNCT0288979635 other results
|
| HAQ-DI, change | -0.5 vs -0.3−0.2 vs placeboNCT0172105711 other results
| -0.8 vs -0.6−0.2 vs placeboNCT0288979636 other results
|
| Modified Sharp score, change | 0.3 vs 0.8−0.5 vs placeboNCT017103582 other results
| 0.1 vs 0.4−0.2 vs placeboNCT028897969 other results
|
ACR20
- baricitinib
- 61.7% vs 39.5%+22.2 vs placeboNCT01721057
11 other results
- 55.4% vs 27.3% NCT01721044
- 65.9% vs 39.5% NCT01721057
- 69.6% vs 40.2% NCT01710358
- 58.6% vs 28.3% NCT02265705
- 76.7% vs 61.9% NCT01711359
- 78.1% vs 61.9% NCT01711359
- 46.3% vs 27.3% NCT01721044
- 44.8% vs 27.3% NCT01721044
- 48.9% vs 27.3% NCT01721044
- 73% vs 55.7% NCT01711359
- 72.6% vs 55.7% NCT01711359
- filgotinib
- 76.6% vs 49.9%+26.7 vs placeboNCT02889796
51 other results
- 69.8% vs 49.9% NCT02889796
- 66% vs 31.1% NCT02873936
- 57.5% vs 31.1% NCT02873936
- 78.1% vs 71.4% NCT02886728
- 81% vs 71.4% NCT02886728
- 80.2% vs 71.4% NCT02886728
- 82.9% vs 85.9% NCT02889796
- 82.9% vs 86.9% NCT02889796
- 78.1% vs 59.2% NCT02889796
- 51.6% vs 31.8% NCT02889796
- 37.3% vs 14.9% NCT02889796
- 79.6% vs 85.9% NCT02889796
- 79.2% vs 86.9% NCT02889796
- 77.7% vs 59.2% NCT02889796
- 45.6% vs 31.8% NCT02889796
- 27.5% vs 14.9% NCT02889796
- 69.4% vs 34.5% NCT02873936
- 51.7% vs 25.7% NCT02873936
- 54.9% vs 34.5% NCT02873936
- 44.4% vs 25.7% NCT02873936
- 74.8% vs 61.8% NCT02886728
- 76.2% vs 68.3% NCT02886728
- 71.4% vs 59.4% NCT02886728
- 52.4% vs 33.4% NCT02886728
- 39.5% vs 16.6% NCT02886728
- 75% vs 61.8% NCT02886728
- 75.5% vs 68.3% NCT02886728
- 76.7% vs 59.4% NCT02886728
- 62.3% vs 33.4% NCT02886728
- 42.1% vs 16.6% NCT02886728
- 73.4% vs 61.8% NCT02886728
- 73.4% vs 68.3% NCT02886728
- 72% vs 59.4% NCT02886728
- 55.6% vs 33.4% NCT02886728
- 37.2% vs 16.6% NCT02886728
- 72.5% vs 29.2% NCT01894516
- 68.6% vs 44.2% NCT01888874
- 65.7% vs 29.2% NCT01894516
- 63.5% vs 44.2% NCT01888874
- 78.6% vs 44.2% NCT01888874
- 66.7% vs 29.2% NCT01894516
- 56.1% vs 44.2% NCT01888874
- 60% vs 44.2% NCT01888874
- 57% vs 44.2% NCT01888874
- 73.3% vs 41.9% NCT01888874
- 61.2% vs 41.9% NCT01888874
- 79.8% vs 41.9% NCT01888874
- 54.9% vs 41.9% NCT01888874
- 60% vs 41.9% NCT01888874
- 55.8% vs 41.9% NCT01888874
- 81% vs 40.9% NCT02885181
ACR50
- baricitinib
- 44.1% vs 21.5%+22.6 vs placeboNCT01721057
13 other results
- 29.4% vs 13.1% NCT01721044
- 33.5% vs 12.7% NCT01721057
- 28.2% vs 8% NCT01721044
- 41.5% vs 21.5% NCT01721057
- 23% vs 13.1% NCT01721044
- 33.6% vs 12.7% NCT01721057
- 20.1% vs 8% NCT01721044
- 57.2% vs 37.6% NCT01711359
- 61.9% vs 37.6% NCT01711359
- 59.7% vs 43.3% NCT01711359
- 63.3% vs 43.3% NCT01711359
- 54.7% vs 32.9% NCT01711359
- 60% vs 32.9% NCT01711359
- filgotinib
- 64.2% vs 66%−1.8 vs placeboNCT02889796
87 other results
- 63.2% vs 63.4% NCT02889796
- 57.9% vs 33.3% NCT02889796
- 47.2% vs 19.8% NCT02889796
- 22.3% vs 5.9% NCT02889796
- 9.1% vs 1.1% NCT02889796
- 60.6% vs 66% NCT02889796
- 57.7% vs 63.4% NCT02889796
- 52.7% vs 33.3% NCT02889796
- 36.5% vs 19.8% NCT02889796
- 12.9% vs 5.9% NCT02889796
- 5.8% vs 1.1% NCT02889796
- 45.6% vs 18.9% NCT02873936
- 42.9% vs 14.9% NCT02873936
- 22.4% vs 7.4% NCT02873936
- 35.3% vs 18.9% NCT02873936
- 32% vs 14.9% NCT02873936
- 21.6% vs 7.4% NCT02873936
- 61.4% vs 48.3% NCT02886728
- 58.6% vs 48.6% NCT02886728
- 58.1% vs 45.7% NCT02886728
- 45.7% vs 28.4% NCT02886728
- 25.7% vs 9.4% NCT02886728
- 16.2% vs 2.9% NCT02886728
- 62.3% vs 48.3% NCT02886728
- 60.6% vs 48.6% NCT02886728
- 61.5% vs 45.7% NCT02886728
- 53.1% vs 28.4% NCT02886728
- 29.3% vs 9.4% NCT02886728
- 13% vs 2.9% NCT02886728
- 59.4% vs 48.3% NCT02886728
- 55.6% vs 48.6% NCT02886728
- 57% vs 45.7% NCT02886728
- 44.4% vs 28.4% NCT02886728
- 20.8% vs 9.4% NCT02886728
- 9.2% vs 2.9% NCT02886728
- 50% vs 16.3% NCT01888874
- 43.5% vs 11.1% NCT01894516
- 43% vs 15.1% NCT01888874
- 31.9% vs 5.6% NCT01894516
- 33.7% vs 12.8% NCT01888874
- 23.2% vs 4.2% NCT01894516
- 17.4% vs 7% NCT01888874
- 21.7% vs 4.2% NCT01894516
- 10.5% vs 5.8% NCT01888874
- 7.2% vs 1.4% NCT01894516
- 4.7% vs 1.2% NCT01888874
- 47.1% vs 16.3% NCT01888874
- 54.8% vs 16.3% NCT01888874
- 37.1% vs 11.1% NCT01894516
- 37.6% vs 15.1% NCT01888874
- 54.8% vs 15.1% NCT01888874
- 25.7% vs 5.6% NCT01894516
- 35.3% vs 12.8% NCT01888874
- 45.2% vs 12.8% NCT01888874
- 18.6% vs 4.2% NCT01894516
- 32.9% vs 7% NCT01888874
- 34.5% vs 7% NCT01888874
- 7.1% vs 4.2% NCT01894516
- 20% vs 5.8% NCT01888874
- 21.4% vs 5.8% NCT01888874
- 10% vs 1.4% NCT01894516
- 4.7% vs 1.2% NCT01888874
- 7.1% vs 1.2% NCT01888874
- 35.4% vs 16.3% NCT01888874
- 35.3% vs 16.3% NCT01888874
- 34.7% vs 11.1% NCT01894516
- 32.9% vs 15.1% NCT01888874
- 34.1% vs 15.1% NCT01888874
- 16.7% vs 5.6% NCT01894516
- 26.8% vs 12.8% NCT01888874
- 34.1% vs 12.8% NCT01888874
- 15.3% vs 4.2% NCT01894516
- 13.4% vs 7% NCT01888874
- 18.8% vs 7% NCT01888874
- 5.6% vs 4.2% NCT01894516
- 7.3% vs 5.8% NCT01888874
- 11.8% vs 5.8% NCT01888874
- 1.4% vs 1.4% NCT01894516
- 2.4% vs 1.2% NCT01888874
- 7.1% vs 1.2% NCT01888874
- 34.9% vs 16.3% NCT01888874
- 27.9% vs 15.1% NCT01888874
- 25.6% vs 12.8% NCT01888874
- 15.1% vs 7% NCT01888874
- 7% vs 5.8% NCT01888874
- 3.5% vs 1.2% NCT01888874
- 47.6% vs 22.7% NCT02885181
ACR70
- baricitinib
- 24.2% vs 7.9%+16.3 vs placeboNCT01721057
17 other results
- 16.9% vs 3.4% NCT01721044
- 18.1% vs 3.1% NCT01721057
- 11.3% vs 2.3% NCT01721044
- 25.3% vs 7.9% NCT01721057
- 13.2% vs 3.4% NCT01721044
- 17.9% vs 3.1% NCT01721057
- 12.6% vs 2.3% NCT01721044
- 42.1% vs 25.2% NCT01711359
- 46% vs 25.2% NCT01711359
- 42.1% vs 21.4% NCT01711359
- 39.5% vs 21.4% NCT01711359
- 30.8% vs 15.7% NCT01711359
- 33.5% vs 15.7% NCT01711359
- 29% vs 0% NCT01469013
- 29% vs 0% NCT01469013
- 21% vs 0% NCT01469013
- 13% vs 0% NCT01469013
- filgotinib
- 44.4% vs 37.7%+6.7 vs placeboNCT02889796
87 other results
- 40.2% vs 34.6% NCT02889796
- 36.2% vs 14.9% NCT02889796
- 26.1% vs 6.7% NCT02889796
- 9.1% vs 1.5% NCT02889796
- 2.7% vs 0.4% NCT02889796
- 39% vs 37.7% NCT02889796
- 35.4% vs 34.6% NCT02889796
- 29.6% vs 14.9% NCT02889796
- 18.5% vs 6.7% NCT02889796
- 3.3% vs 1.5% NCT02889796
- 1.3% vs 0.4% NCT02889796
- 32% vs 8.1% NCT02873936
- 21.8% vs 6.8% NCT02873936
- 6.1% vs 2.7% NCT02873936
- 20.3% vs 8.1% NCT02873936
- 14.4% vs 6.8% NCT02873936
- 8.5% vs 2.7% NCT02873936
- 45.2% vs 29.8% NCT02886728
- 39.5% vs 32.2% NCT02886728
- 40% vs 26% NCT02886728
- 29% vs 13.2% NCT02886728
- 11.4% vs 3.8% NCT02886728
- 4.3% vs 0.7% NCT02886728
- 47.8% vs 29.8% NCT02886728
- 45.9% vs 32.2% NCT02886728
- 43.8% vs 26% NCT02886728
- 32.9% vs 13.2% NCT02886728
- 13% vs 3.8% NCT02886728
- 3.1% vs 0.7% NCT02886728
- 40.1% vs 29.8% NCT02886728
- 37.2% vs 32.2% NCT02886728
- 40.1% vs 26% NCT02886728
- 27.1% vs 13.2% NCT02886728
- 6.3% vs 3.8% NCT02886728
- 1.9% vs 0.7% NCT02886728
- 29.1% vs 9.3% NCT01888874
- 13% vs 2.8% NCT01894516
- 24.4% vs 8.1% NCT01888874
- 17.4% vs 2.8% NCT01894516
- 18.6% vs 7% NCT01888874
- 11.6% vs 1.4% NCT01894516
- 4.7% vs 3.5% NCT01888874
- 4.3% vs 2.8% NCT01894516
- 5.8% vs 1.2% NCT01888874
- 1.4% vs 0% NCT01894516
- 1.2% vs 1.2% NCT01888874
- 32.9% vs 9.3% NCT01888874
- 39.3% vs 9.3% NCT01888874
- 18.6% vs 2.8% NCT01894516
- 21.2% vs 8.1% NCT01888874
- 31% vs 8.1% NCT01888874
- 11.4% vs 2.8% NCT01894516
- 23.5% vs 7% NCT01888874
- 27.4% vs 7% NCT01888874
- 5.7% vs 1.4% NCT01894516
- 14.1% vs 3.5% NCT01888874
- 10.7% vs 3.5% NCT01888874
- 1.4% vs 2.8% NCT01894516
- 7.1% vs 1.2% NCT01888874
- 3.6% vs 1.2% NCT01888874
- 1.4% vs 0% NCT01894516
- 0% vs 1.2% NCT01888874
- 4.8% vs 1.2% NCT01888874
- 22% vs 9.3% NCT01888874
- 23.5% vs 9.3% NCT01888874
- 8.3% vs 2.8% NCT01894516
- 15.9% vs 8.1% NCT01888874
- 18.8% vs 8.1% NCT01888874
- 6.9% vs 2.8% NCT01894516
- 11% vs 7% NCT01888874
- 14.1% vs 7% NCT01888874
- 8.3% vs 1.4% NCT01894516
- 7.3% vs 3.5% NCT01888874
- 9.4% vs 3.5% NCT01888874
- 1.4% vs 2.8% NCT01894516
- 2.4% vs 1.2% NCT01888874
- 5.9% vs 1.2% NCT01888874
- 0% vs 0% NCT01894516
- 0% vs 1.2% NCT01888874
- 2.4% vs 1.2% NCT01888874
- 20.9% vs 9.3% NCT01888874
- 14% vs 8.1% NCT01888874
- 9.3% vs 7% NCT01888874
- 5.8% vs 3.5% NCT01888874
- 2.3% vs 1.2% NCT01888874
- 1.2% vs 1.2% NCT01888874
- 38.1% vs 13.6% NCT02885181
DAS28-CRP remission
- baricitinib
- —Trial running · NCT04870203
- filgotinib
- 54.5% vs 50.8%+3.7 vs placeboNCT02889796
35 other results
- 50.3% vs 46.1% NCT02889796
- 48.4% vs 16.2% NCT02889796
- 34.1% vs 9.3% NCT02889796
- 13.7% vs 2.9% NCT02889796
- 5.1% vs 0.6% NCT02889796
- 44.8% vs 50.8% NCT02889796
- 42.9% vs 46.1% NCT02889796
- 35.2% vs 16.2% NCT02889796
- 23.8% vs 9.3% NCT02889796
- 8.8% vs 2.9% NCT02889796
- 1.7% vs 0.6% NCT02889796
- 30.6% vs 12.2% NCT02873936
- 22.4% vs 8.1% NCT02873936
- 10.2% vs 2.7% NCT02873936
- 26.1% vs 12.2% NCT02873936
- 25.5% vs 8.1% NCT02873936
- 11.8% vs 2.7% NCT02873936
- 46.2% vs 31.5% NCT02886728
- 43.3% vs 34.4% NCT02886728
- 42.4% vs 29.1% NCT02886728
- 29.5% vs 17.1% NCT02886728
- 19.5% vs 4.8% NCT02886728
- 10% vs 1% NCT02886728
- 53.4% vs 31.5% NCT02886728
- 52.6% vs 34.4% NCT02886728
- 54.1% vs 29.1% NCT02886728
- 39.7% vs 17.1% NCT02886728
- 16.6% vs 4.8% NCT02886728
- 7.2% vs 1% NCT02886728
- 43% vs 31.5% NCT02886728
- 42% vs 34.4% NCT02886728
- 42.5% vs 29.1% NCT02886728
- 31.9% vs 17.1% NCT02886728
- 15% vs 4.8% NCT02886728
- 4.3% vs 1% NCT02886728
HAQ-DI, change
- baricitinib
- -0.5 vs -0.3−0.2 vs placeboNCT01721057
11 other results
- -0.4 vs -0.2 NCT01721044
- -0.5 vs -0.3 NCT01721057
- -0.4 vs -0.2 NCT01721044
- -0.7 vs -0.3 NCT01710358
- -0.6 vs -0.3 NCT02265705
- -1.0 vs -0.7 NCT01711359
- -0.9 vs -0.7 NCT01711359
- -0.5 vs -0.1 NCT01469013
- -0.4 vs -0.1 NCT01469013
- -0.4 vs -0.1 NCT01469013
- -0.3 vs -0.1 NCT01469013
- filgotinib
- -0.8 vs -0.6−0.2 vs placeboNCT02889796
36 other results
- -0.7 vs -0.4 NCT02889796
- -0.9 vs -0.7 NCT02889796
- -0.4 vs -0.3 NCT02889796
- -0.3 vs -0.1 NCT02889796
- -0.9 vs -0.7 NCT02889796
- -0.8 vs -0.6 NCT02889796
- -0.6 vs -0.4 NCT02889796
- -0.8 vs -0.7 NCT02889796
- -0.3 vs -0.3 NCT02889796
- -0.2 vs -0.1 NCT02889796
- -0.8 vs -0.7 NCT02889796
- -0.8 vs -0.4 NCT02873936
- -0.6 vs -0.2 NCT02873936
- -0.4 vs -0.2 NCT02873936
- -0.6 vs -0.4 NCT02873936
- -0.5 vs -0.2 NCT02873936
- -0.3 vs -0.2 NCT02873936
- -0.9 vs -0.8 NCT02886728
- -0.8 vs -0.6 NCT02886728
- -0.9 vs -0.9 NCT02886728
- -0.5 vs -0.3 NCT02886728
- -0.3 vs -0.2 NCT02886728
- -0.9 vs -0.9 NCT02886728
- -0.9 vs -0.8 NCT02886728
- -0.8 vs -0.6 NCT02886728
- -1.0 vs -0.9 NCT02886728
- -0.6 vs -0.3 NCT02886728
- -0.4 vs -0.2 NCT02886728
- -1 vs -0.9 NCT02886728
- -0.9 vs -0.8 NCT02886728
- -0.8 vs -0.6 NCT02886728
- -0.9 vs -0.9 NCT02886728
- -0.5 vs -0.3 NCT02886728
- -0.4 vs -0.2 NCT02886728
- -1.0 vs -0.9 NCT02886728
- -0.7 vs -0.4 NCT02885181
Modified Sharp score, change
- baricitinib
- 0.3 vs 0.8−0.5 vs placeboNCT01710358
2 other results
- 0.4 vs 0.6 NCT01711359
- 0.3 vs 0.6 NCT01711359
- filgotinib
- 0.1 vs 0.4−0.2 vs placeboNCT02889796
9 other results
- 0.2 vs 0.9 NCT02889796
- 0.2 vs 0.4 NCT02889796
- 0.5 vs 0.9 NCT02889796
- -0.0 vs 0.5 NCT02886728
- 0.3 vs 0.8 NCT02886728
- 0.2 vs 0.5 NCT02886728
- 0.3 vs 0.8 NCT02886728
- 0.2 vs 0.5 NCT02886728
- 0.2 vs 0.8 NCT02886728
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety
Coverage. baricitinib: 9 of 9 rows · filgotinib: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | baricitinib Rows use multiple source trials | filgotinib Rows use multiple source trials |
|---|---|---|
| Boolean Remission responder rate · % of participants | 12.1% (n=487) vs 2.7% (n=488) placebo @ 24wka,b,c NCT01710358 · Phase 3 4 other source trials18.9% (n=159) vs 8.6% (n=210) Methotrexate @ 24wk NCT01711359 · Phase 3 16.3% (n=215) vs 8.6% (n=210) Methotrexate @ 24wk NCT01711359 · Phase 3 · combination 4% (n=174) vs 1.1% (n=176) placebo @ 24wk2 mg NCT01721044 · Phase 3 6.8% (n=177) vs 1.1% (n=176) placebo @ 24wk4 mg NCT01721044 · Phase 3 | 11.6% (n=86) vs 1.2% (n=86) placebo @ 24wk200 mg QDd,a,b,c NCT01888874 · Phase 2 · registry result, not featured evidence show 5 more doses19% (n=84) vs 1.2% (n=86) placebo @ 24wk100 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 8.2% (n=85) vs 1.2% (n=86) placebo @ 24wk100 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 3.5% (n=85) vs 1.2% (n=86) placebo @ 24wk50 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 11% (n=82) vs 1.2% (n=86) placebo @ 24wk50 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 5.8% (n=86) vs 1.2% (n=86) placebo @ 24wk25 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence |
| CDAI absolute change · score | -26.44 vs NA placebo score @ 52wkb NCT01710358 · Phase 3 2 other source trials-28.94 vs -21.95 Methotrexate score @ 52wk NCT01711359 · Phase 3 -30.72 vs -21.95 Methotrexate score @ 52wk NCT01711359 · Phase 3 · combination | -33.6 vs -31.2 MTX score @ 52wk200 mgd,b NCT02886728 · Phase 3 · monotherapy show 2 more doses-33.8 vs -31.2 MTX score @ 52wk200 mg NCT02886728 · Phase 3 · combination -31.9 vs -31.2 MTX score @ 52wk100 mg NCT02886728 · Phase 3 · combination |
| DAS28-CRP absolute change · score | -2.74 vs -2.01 Methotrexate score @ 24wkd,b NCT01711359 · Phase 3 show 1 more dose-2.82 vs -2.01 Methotrexate score @ 24wk NCT01711359 · Phase 3 · combination | -2.9 vs -2.1 placebo score @ 24wk200 mgd,b NCT02873936 · Phase 3 show 1 more dose-2.6 vs -2.1 placebo score @ 24wk100 mg NCT02873936 · Phase 3 |
| FACIT-Fatigue absolute change · score | 10.8 vs NA placebo score @ 52wkb NCT01710358 · Phase 3 2 other source trials11.3 vs 9.1 Methotrexate score @ 52wk NCT01711359 · Phase 3 12.6 vs 9.1 Methotrexate score @ 52wk NCT01711359 · Phase 3 · combination | 11.5 vs 11.3 MTX score @ 52wk200 mgd,b NCT02886728 · Phase 3 · monotherapy show 2 more doses11.7 vs 11.3 MTX score @ 52wk200 mg NCT02886728 · Phase 3 · combination 11.9 vs 11.3 MTX score @ 52wk100 mg NCT02886728 · Phase 3 · combination |
| SDAI absolute change · score | -23.78 vs -14.55 placebo score @ 24wk4 mgd,b,c NCT01721057 · Phase 3 show 1 more dose-21.87 vs -14.55 placebo score @ 24wk2 mg NCT01721057 · Phase 3 | -32.1 vs -24.9 placebo score @ 24wk200 mgd,b,c NCT02873936 · Phase 3 show 1 more dose-28.8 vs -24.9 placebo score @ 24wk100 mg NCT02873936 · Phase 3 |
| Dropout rate | 5.9%Baricitinibe NCT01710358 · Phase 3 show 43 more results—Baricitinib Follow-up NCT01710358 · Phase 3 —Baricitinib Treatment A NCT01710358 · Phase 3 —BaricitinibTreatment B NCT01710358 · Phase 3 15%Baricitinib NCT01711359 · Phase 3 19.5%Baricitinib + MTX NCT01711359 · Phase 3 · combination —Baricitinib + MTX - Follow-up NCT01711359 · Phase 3 · combination —Baricitinib - Follow-up NCT01711359 · Phase 3 6.2%4 mg NCT02265705 · Phase 3 —4 mg NCT02265705 · Phase 3 —4 mg NCT02265705 · Phase 3 —Placebo to Baricitinib Treatment P NCT02265705 · Phase 3 —4 mg NCT01469013 · Phase 2 —2 mg NCT01469013 · Phase 2 —8 mg NCT01469013 · Phase 2 —1 mg NCT01469013 · Phase 2 —4 mg NCT01721057 · Phase 3 10.1%4 mg NCT01721057 · Phase 3 —4 mg NCT01721057 · Phase 3 —2 mg NCT01721057 · Phase 3 8.3%2 mg NCT01721057 · Phase 3 —2 mg NCT01721057 · Phase 3 10.7%4 mg NCT01721044 · Phase 3 —4 mg NCT01721044 · Phase 3 —4 mg NCT01721044 · Phase 3 9.8%2 mg NCT01721044 · Phase 3 —2 mg NCT01721044 · Phase 3 —2 mg NCT01721044 · Phase 3 51.7%4 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 51.1%2 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 55.7%4 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled 60.8%2 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 33.7%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 94.1%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 75.5%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 70.2%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 95.8%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 100%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence 76.9%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence 72.8%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence | 8.8%200 mge NCT02873936 · Phase 3 show 26 more results15%100 mg NCT02873936 · Phase 3 17.1%200 mg NCT02886728 · Phase 3 · monotherapy 17.3%200 mg NCT02886728 · Phase 3 · combination 15.5%100 mg NCT02886728 · Phase 3 · combination 11.1%200 mg NCT02889796 · Phase 3 12.1%100 mg NCT02889796 · Phase 3 52.1%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 53%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 53.7%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence 61.6%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence 0%Filgonitib NCT03926195 · Phase 2 · registry result, not featured evidence 67.6%Filgotinib Darwin 1 NCT02065700 · Phase 2 · registry result, not featured evidence 66.5%Filgotinib Darwin 2 NCT02065700 · Phase 2 · registry result, not featured evidence 0% NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy 4.3%200 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 4.3%100 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 6.9%50 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 7%200 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 1.2%100 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 8.2%100 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 5.9%50 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 7.3%50 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 10.5%25 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3.7%Baricitinibe NCT01710358 · Phase 3 show 43 more results—Baricitinib Follow-up NCT01710358 · Phase 3 —Baricitinib Treatment A NCT01710358 · Phase 3 —BaricitinibTreatment B NCT01710358 · Phase 3 6.3%Baricitinib NCT01711359 · Phase 3 11.2%Baricitinib + MTX NCT01711359 · Phase 3 · combination —Baricitinib + MTX - Follow-up NCT01711359 · Phase 3 · combination —Baricitinib - Follow-up NCT01711359 · Phase 3 1.4%4 mg NCT02265705 · Phase 3 —4 mg NCT02265705 · Phase 3 —4 mg NCT02265705 · Phase 3 —Placebo to Baricitinib Treatment P NCT02265705 · Phase 3 —4 mg NCT01469013 · Phase 2 —2 mg NCT01469013 · Phase 2 —8 mg NCT01469013 · Phase 2 —1 mg NCT01469013 · Phase 2 —4 mg NCT01721057 · Phase 3 5.3%4 mg NCT01721057 · Phase 3 —4 mg NCT01721057 · Phase 3 —2 mg NCT01721057 · Phase 3 4.4%2 mg NCT01721057 · Phase 3 —2 mg NCT01721057 · Phase 3 5.6%4 mg NCT01721044 · Phase 3 —4 mg NCT01721044 · Phase 3 —4 mg NCT01721044 · Phase 3 4%2 mg NCT01721044 · Phase 3 —2 mg NCT01721044 · Phase 3 —2 mg NCT01721044 · Phase 3 13.5%4 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 12.6%2 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 8.3%4 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled 5.7%2 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 6%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 12.5%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 21.8%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 18.1%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 11.5%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 10.9%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence 14.5%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence 16.7%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence | 2%200 mge NCT02873936 · Phase 3 show 26 more results3.3%100 mg NCT02873936 · Phase 3 2.4%200 mg NCT02886728 · Phase 3 · monotherapy 3.1%200 mg NCT02886728 · Phase 3 · combination 2.4%100 mg NCT02886728 · Phase 3 · combination 3.6%200 mg NCT02889796 · Phase 3 1.7%100 mg NCT02889796 · Phase 3 12.3%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 13.4%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 14%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence 12.2%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —Filgonitib NCT03926195 · Phase 2 · registry result, not featured evidence 33.2%Filgotinib Darwin 1 NCT02065700 · Phase 2 · registry result, not featured evidence 42.6%Filgotinib Darwin 2 NCT02065700 · Phase 2 · registry result, not featured evidence 0% NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy 1.4%200 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 0%100 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 0%50 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 1.2%200 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 0%100 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 3.5%100 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 1.2%50 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 2.4%50 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 3.5%25 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —Baricitinibe NCT01710358 · Phase 3 show 43 more results0%Baricitinib Follow-up NCT01710358 · Phase 3 5.3%Baricitinib Treatment A NCT01710358 · Phase 3 3.8%BaricitinibTreatment B NCT01710358 · Phase 3 7.5%Baricitinib NCT01711359 · Phase 3 7.9%Baricitinib + MTX NCT01711359 · Phase 3 · combination 0%Baricitinib + MTX - Follow-up NCT01711359 · Phase 3 · combination 0%Baricitinib - Follow-up NCT01711359 · Phase 3 2.8%4 mg NCT02265705 · Phase 3 1.7%4 mg NCT02265705 · Phase 3 2.5%4 mg NCT02265705 · Phase 3 9.5%Placebo to Baricitinib Treatment P NCT02265705 · Phase 3 0%4 mg NCT01469013 · Phase 2 4.2%2 mg NCT01469013 · Phase 2 4.2%8 mg NCT01469013 · Phase 2 0%1 mg NCT01469013 · Phase 2 5.3%4 mg NCT01721057 · Phase 3 —4 mg NCT01721057 · Phase 3 4.5%4 mg NCT01721057 · Phase 3 2.6%2 mg NCT01721057 · Phase 3 —2 mg NCT01721057 · Phase 3 0%2 mg NCT01721057 · Phase 3 —4 mg NCT01721044 · Phase 3 0%4 mg NCT01721044 · Phase 3 10.7%4 mg NCT01721044 · Phase 3 —2 mg NCT01721044 · Phase 3 11.1%2 mg NCT01721044 · Phase 3 4.6%2 mg NCT01721044 · Phase 3 31.3%4 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 29.5%2 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 23.7%4 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled 22.9%2 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled 20%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 30%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 37.7%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence 27.7%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence | 4.1%200 mge NCT02873936 · Phase 3 show 26 more results5.2%100 mg NCT02873936 · Phase 3 8.1%200 mg NCT02886728 · Phase 3 · monotherapy 6.3%200 mg NCT02886728 · Phase 3 · combination 6.3%100 mg NCT02886728 · Phase 3 · combination 7.4%200 mg NCT02889796 · Phase 3 8.3%100 mg NCT02889796 · Phase 3 24.1%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 22.1%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 24.6%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence 25.9%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence 3.7%200 mg NCT03926195 · Phase 2 · registry result, not featured evidence 12.8%200 mg NCT03926195 · Phase 2 · registry result, not featured evidence 14.3%200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —Filgonitib NCT03926195 · Phase 2 · registry result, not featured evidence 16.9%Filgotinib Darwin 1 NCT02065700 · Phase 2 · registry result, not featured evidence 19.8%Filgotinib Darwin 2 NCT02065700 · Phase 2 · registry result, not featured evidence 0% NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy 4.3%200 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 3.5%100 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 2.8%50 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 2.3%200 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 3.6%100 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 3.4%100 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 0%50 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 0%50 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 2.3%25 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | e alanine aminotransferase increased 0% (placebo 0%) anaemia 0% (placebo 0%) back pain 0% (placebo 0%) NCT01710358 · Phase 3 show 30 more resultsnasopharyngitis 7.6% (placebo 6.1%) urinary tract infection 4.3% (placebo 0%) bronchitis 3.9% (placebo 0%) NCT01710358 · Phase 3 nasopharyngitis 5.7% (placebo 6.1%) upper respiratory tract infection 3.1% (placebo 0%) bronchitis 2.8% (placebo 0%) NCT01710358 · Phase 3 nasopharyngitis 10.1% upper respiratory tract infection 7.5% gastroenteritis 6.3% NCT01711359 · Phase 3 nasopharyngitis 9.8% nausea 9.3% upper respiratory tract infection 7.4% NCT01711359 · Phase 3 · combination abdominal discomfort 0% abdominal pain upper 0% alanine aminotransferase increased 0% NCT01711359 · Phase 3 · combination 4 mg upper respiratory tract infection 19.3% (placebo 0%) hyperlipidaemia 11% (placebo 0%) urinary tract infection 9% (placebo 0%) NCT02265705 · Phase 3 4 mg arthralgia 5.2% (placebo 0%) abdominal pain 0% (placebo 0%) abdominal pain upper 0% (placebo 0%) NCT02265705 · Phase 3 4 mg upper respiratory tract infection 9.2% (placebo 0%) hyperlipidaemia 7.5% (placebo 0%) benign prostatic hyperplasia 7.1% (placebo 0%) NCT02265705 · Phase 3 blood creatine phosphokinase increased 6.8% (placebo 0%) upper respiratory tract infection 6.8% (placebo 0%) nasopharyngitis 5.4% (placebo 0%) NCT02265705 · Phase 3 4 mg blood creatine phosphokinase increased 8.3% (placebo 4.1%) liver function test abnormal 8.3% (placebo 0%) nasopharyngitis 8.3% (placebo 12.2%) NCT01469013 · Phase 2 2 mg hepatic function abnormal 12.5% (placebo 0%) nasopharyngitis 8.3% (placebo 12.2%) cystitis 4.2% (placebo 4.1%) NCT01469013 · Phase 2 8 mg blood creatine phosphokinase increased 12.5% (placebo 4.1%) hepatic function abnormal 12.5% (placebo 0%) hypercholesterolaemia 12.5% (placebo 0%) NCT01469013 · Phase 2 1 mg nasopharyngitis 8.3% (placebo 12.2%) anaemia 4.2% (placebo 0%) chronic sinusitis 4.2% (placebo 0%) NCT01469013 · Phase 2 4 mg upper respiratory tract infection 10.6% (placebo 0%) nasopharyngitis 7.9% (placebo 0%) blood creatine phosphokinase increased 6.6% (placebo 5.9%) NCT01721057 · Phase 3 4 mg cough 4.5% (placebo 0%) dyspnoea 4.5% (placebo 0%) gastritis 4.5% (placebo 0%) NCT01721057 · Phase 3 2 mg headache 6.6% (placebo 0%) upper respiratory tract infection 6.1% (placebo 0%) urinary tract infection 5.2% (placebo 0%) NCT01721057 · Phase 3 2 mg abdominal pain 0% (placebo 0%) abdominal pain upper 0% (placebo 0%) acne 0% (placebo 0%) NCT01721057 · Phase 3 4 mg cervicitis 5.6% (placebo 0%) abdominal pain 0% (placebo 0%) abdominal pain upper 0% (placebo 0%) NCT01721044 · Phase 3 4 mg headache 6.8% (placebo 0%) bronchitis 5.6% (placebo 0%) nausea 5.6% (placebo 0%) NCT01721044 · Phase 3 2 mg cellulitis 11.1% (placebo 0%) insomnia 11.1% (placebo 0%) lymphopenia 11.1% (placebo 0%) NCT01721044 · Phase 3 2 mg headache 9.8% (placebo 0%) upper respiratory tract infection 8.6% (placebo 0%) nasopharyngitis 6.9% (placebo 5.3%) NCT01721044 · Phase 3 4 mg covid-19 23.3% nasopharyngitis 13.8% urinary tract infection 11.4% NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 2 mg covid-19 20.8% nasopharyngitis 11.6% urinary tract infection 11.3% NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 4 mg bronchitis 11.3% nasopharyngitis 11.3% upper respiratory tract infection 10.9% NCT01885078 · Phase 3 · registry result, not featured evidence 4 mg bronchitis 10.9% nasopharyngitis 9.8% influenza 9.4% NCT01885078 · Phase 3 · registry result, not featured evidence 2 mg upper respiratory tract infection 19.5% urinary tract infection 17.8% bronchitis 16.2% NCT01885078 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 9.1% upper respiratory tract infection 7.8% bronchitis 7.4% NCT01885078 · Phase 3 · registry result, not featured evidence | 200 mge nasopharyngitis 10.2% (placebo 4.7%) bronchitis 5.4% (placebo 5.4%) headache 5.4% (placebo 1.4%) NCT02873936 · Phase 3 show 25 more results100 mg headache 5.9% (placebo 1.4%) nasopharyngitis 5.9% (placebo 4.7%) upper respiratory tract infection 5.9% (placebo 4.1%) NCT02873936 · Phase 3 200 mg nausea 12.3% upper respiratory tract infection 10.1% alanine aminotransferase increased 5.5% NCT02886728 · Phase 3 · combination 200 mg nasopharyngitis 9.1% (placebo 5.3%) upper respiratory tract infection 8.6% (placebo 2.9%) nausea 5.5% (placebo 1.5%) NCT02889796 · Phase 3 100 mg upper respiratory tract infection 10.2% (placebo 2.9%) nasopharyngitis 10% (placebo 5.3%) alanine aminotransferase increased 5.2% (placebo 2.3%) NCT02889796 · Phase 3 200 mg covid-19 18.3% nasopharyngitis 13.1% upper respiratory tract infection 11% NCT03025308 · Phase 3 · registry result, not featured evidence 200 mg covid-19 17.3% upper respiratory tract infection 13.1% rheumatoid arthritis 11.9% NCT03025308 · Phase 3 · registry result, not featured evidence 100 mg covid-19 15.3% nasopharyngitis 15.1% rheumatoid arthritis 13.9% NCT03025308 · Phase 3 · registry result, not featured evidence 100 mg covid-19 18.5% rheumatoid arthritis 12.2% upper respiratory tract infection 11.9% NCT03025308 · Phase 3 · registry result, not featured evidence 200 mg nasopharyngitis 7.4% (placebo 7.3%) dyslipidaemia 3.7% (placebo 0%) headache 3.7% (placebo 1.8%) NCT03926195 · Phase 2 · registry result, not featured evidence 200 mg covid-19 15.4% (placebo 0%) ankylosing spondylitis 7.7% (placebo 0%) latent tuberculosis 7.7% (placebo 0%) NCT03926195 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 57.1% (placebo 7.3%) covid-19 42.9% (placebo 0%) alanine aminotransferase increased 14.3% (placebo 0%) NCT03926195 · Phase 2 · registry result, not featured evidence hypertension 15.1% urinary tract infection 14.5% nasopharyngitis 14.1% NCT02065700 · Phase 2 · registry result, not featured evidence mycobacterium tuberculosis complex test positive 16.5% upper respiratory tract infection 15.3% hypercholesterolaemia 12.4% NCT02065700 · Phase 2 · registry result, not featured evidence asthenia 9.5% (placebo 0%) blood creatine phosphokinase increased 4.8% (placebo 0%) dyspepsia 4.8% (placebo 0%) NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy 200 mg QD anaemia 5.8% (placebo 0%) upper respiratory tract infection 5.8% (placebo 2.8%) urinary tract infection 5.8% (placebo 1.4%) NCT01894516 · Phase 2 · registry result, not featured evidence 100 mg QD urinary tract infection 8.2% (placebo 1.4%) hypercholesterolaemia 5.9% (placebo 4.2%) hypertriglyceridaemia 5.9% (placebo 1.4%) NCT01894516 · Phase 2 · registry result, not featured evidence 50 mg QD headache 5.6% (placebo 1.4%) hypercholesterolaemia 5.6% (placebo 4.2%) hypertension 4.2% (placebo 5.6%) NCT01894516 · Phase 2 · registry result, not featured evidence 200 mg QD headache 7% (placebo 4.7%) hypercholesterolaemia 5.8% (placebo 0%) hypertension 4.7% (placebo 2.3%) NCT01888874 · Phase 2 · registry result, not featured evidence 100 mg BID hypercholesterolaemia 4.8% (placebo 0%) nasopharyngitis 4.8% (placebo 4.7%) headache 2.4% (placebo 4.7%) NCT01888874 · Phase 2 · registry result, not featured evidence 100 mg QD hypertension 5% (placebo 2.3%) nasopharyngitis 2.5% (placebo 4.7%) upper respiratory tract infection 1.7% (placebo 1.2%) NCT01888874 · Phase 2 · registry result, not featured evidence 50 mg BID upper respiratory tract infection 5.1% (placebo 1.2%) vomiting 5.1% (placebo 1.2%) hypertension 3.4% (placebo 2.3%) NCT01888874 · Phase 2 · registry result, not featured evidence 50 mg QD nasopharyngitis 9.8% (placebo 4.7%) nausea 8.5% (placebo 3.5%) hypertension 3.7% (placebo 2.3%) NCT01888874 · Phase 2 · registry result, not featured evidence 25 mg BID headache 7% (placebo 4.7%) gastroenteritis 5.8% (placebo 0%) nasopharyngitis 4.7% (placebo 4.7%) NCT01888874 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
baricitinib
show 13 more results
+ 75 further endpoints in the CSV export.
filgotinib
show 29 more results
show 30 more results
show 35 more results
show 35 more results
show 35 more results
show 35 more results
show 35 more results
show 5 more results
show 35 more results
show 23 more results
show 17 more results
show 6 more results
+ 256 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: baricitinib's landscape · filgotinib's landscape